| Revenue growth | 15% YoY growth in Q1 FY27. |
|---|---|
| Margins | EBITDA margins improved 349 bps YoY to 18.09%. |
| Demand visibility | Strong pull-led growth in critical care and infertility segments. |
| Management confidence | High, citing structural pivot to IP-owned model and Indore scale-up. |
Growth
Revenue grew 15% YoY; PAT increased 82% YoY to ₹22 Cr, driven by significant margin expansion from 14.6% to 18.1%.
Outlook
Targeting 30% capacity utilization at Indore by FY26. Focused on 'First-in-India' launches and reducing Chinese API dependence.
Risks
Regulatory delays for EU-GMP/USFDA certifications at Indore; high dependence on hospital-channel execution and specialized injector training.
Last quarter's promises, checked
Delivered
- Target 30% capacity utilization at Indore by year-end → Delivered 30% (= BEAT)
- Commitment to reach Indore EBITDA breakeven by Q4 → Delivered breakeven (= BEAT)
- Guided 15% annual revenue growth → Delivered ~15% (₹820Cr to ₹940.5Cr) (= BEAT)
Partly delivered
- Guided EU-GMP certification by Q4 → Audit completed Dec 2025 but certificate still pending (= PARTIAL)
Investor Presentation filed with BSE, NSE: GUFICBIO. Summary written with AI assistance from the document.
Gufic BioSciences Ltd: key numbers
- Share price
- ₹423.75
- Market cap
- ₹4,249 Cr
- Revenue (annual)
- ₹944.0 Cr
- Net profit (annual)
- ₹64.21 Cr
- P/E (TTM)
- 57.9×Sector 50.4×
- Promoter holding
- 72.50%+0.00% QoQ
- FII holding
- 0.47%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Gufic BioSciences Ltd
All →Gufic BioSciences Legal & Regulatory
NSE rejected Gufic Biosciences' waiver application regarding a ₹1.72 lakh penalty for Regulation 17(1A) non-compliance. The company will pay the fine by October 03, 2026.
- Value
- ₹0.02 Cr
Gufic BioSciences Credit Rating
Gufic Biosciences announced that CRISIL Ratings has reaffirmed its credit ratings on the company's total bank loan facilities of ₹516 Crore.
- Value
- ₹516.0 Cr
Gufic BioSciences Annual General Meeting
Gufic Biosciences held its 42nd Annual General Meeting on September 4, 2026, where shareholders adopted financial statements and approved the final dividend declaration.
Gufic BioSciences Management Change
Gufic Biosciences Limited announced the promotions of Ms. Ami Shah to Head-Legal and Mr. Pinak Padhya to President of Sales & Marketing, effective September 2, 2026.
Gufic BioSciences Earnings Call Transcript: Key Takeaways
Gufic reports strong Q1 FY27 growth, driven by Indore plant ramp-up and expansion into high-margin complex injectables like GLP-1 (Semaglutide) and Botulinum Toxin.
- Call
- Guides 15% growth
Gufic BioSciences Q1 FY27 Results: Net Profit ₹22.3 Cr, Up 70.2% YoY
Gufic BioSciences Ltd reported revenue from operations of ₹260.8 Cr (+16.6% YoY) and net profit of ₹22.3 Cr (+70.2% YoY) for Q1 FY27.
- Key figure
- Net profit ₹22.3 Cr · +70.2% YoY